A PubMed Central-hosted review of peptide-based obesity treatments describes "nausea, vomiting and loss of appetite" as common effects of the GLP-1 drug class (pmc.ncbi.nlm.nih.gov)
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications primarily used for managing type 2 diabetes and, in some formulations, for weight management in adults with BMI 30 kg/m or 27 kg/m with weight-related comorbidities
Key timing considerations: Side effect profile tends to be somewhat milder than semaglutide, which may reduce the importance of sleep-through timing Same 48-hour minimum spacing rule applies if changing injection days Pre-filled pen format means no reconstitution time, making spontaneous timing adjustments easier Many dulaglutide users report minimal side effects after the first month, at which point timing becomes purely a convenience decision Retatrutide (weekly injectable, investigational) Dosing frequency: Once weekly Half-life: Data from Phase 2 trials suggest approximately 6 days Peak concentration: Approximately 24 to 72 hours after injection Recommended timing approach: As a triple agonist (GLP-1/GIP/glucagon), retatrutide may produce a different side effect profile than pure GLP-1 or dual GLP-1/GIP agonists
Whether Klarity is in-network with your specific Anthem plan depends on the plan type and network
WeightWatchers is, however, LegitScript certified and uses only FDA-approved GLP-1s
(2025) Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial Mona Mashayekhi, et al
